Fundamentos e objetivos: Em estudos recentes sobre interven&ccedil;&atilde;o coron&aacute;ria percut&acirc;nea prim&aacute;ria (PPCI), a bivalirudina em compara&ccedil;&atilde;o com a heparina tem sido associada ao aumento do risco de trombose de stent (ST), com taxas relatadas de ST muito vari&aacute;veis. O objetivo deste estudo foi descrever a incid&ecirc;ncia de &ldquo;mundo real&rdquo; e os resultados de ST definitiva,<a href="https://solaci.org/en/2015/06/24/taxas-de-trombose-de-stent-em-pacientes-com-stemi-2/" title="Read more" >...</a>

This randomized trial of a single center with consent obtained after randomization compared the use of bivalirudin versus heparin with the use of glycoprotein inhibitors arescue only in patients having ST segment elevation myocardial infarction.The primary efficacy endpoint was a composite of death, stroke, and myocardial revascularization of the target lesion and the primary safety<a href="https://solaci.org/en/2015/06/24/heat-ppci-bivalirudin-raises-major-cardiac-events-and-does-not-reduce-bleeding-the-most-controversial-and-criticized-study-at-the-acc-14/" title="Read more" >...</a>

Presentation Summary: The French National Registry included patients admitted with acute myocardial infarction between 1995 and 2010 (n = 6707). Over time, authors noted a reduction in the age of presentation, especially in women under 60 years with increased incidence of smoking and obesity. Pain-center time was significantly reduced, while increasing the number of patients<a href="https://solaci.org/en/2015/06/24/fast-mi-ami-improved-the-survival-associated-with-the-clinical-characteristics-changes-of-patients-in-the-french-national-registry/" title="Read more" >...</a>

Background: Octogenarian patients represent an increasingly growing population. In addition, this age group has a higher proportion of co-morbidities with more extensive and complex coronary disease. However, they have often been excluded from major studies, whose average age is usually 60 years. Despite having a more complex coronary anatomy, the role of pharmacological stent (DES)<a href="https://solaci.org/en/2015/06/24/xima-randomized-prospective-study-comparing-everolimus-eluting-stents-versus-conventional-stent-implantation-in-octogenarians/" title="Read more" >...</a>

The HORIZONS AMI trial showed the usefulness of bivalirudin in reducing mortality and bleeding compared with the use of heparin plus glycoprotein IIBIIIA. However, some questions remained unanswered: What is the utility of starting the infusion during the ambulance journey? Is it possible to reduce the risk of acute thrombosis by extending bivalirudin infusion or<a href="https://solaci.org/en/2015/06/24/euromax-bivalirudin-during-transport-to-primary-angioplasty/" title="Read more" >...</a>

Bivalirudin reduced mortality and bleeding compared to heparin and glycoprotein IIbIIIa in HORIZONS- AMI study. However there was a higher rate of acute stent thrombosis in patients receiving bivalirudin. This randomized study (&gt; 90 % randomized in the ambulance) enrolled 2218 patients with ASTEMIto prolonged infusion of bivalirudin compared with heparin -associated glycoprotein inhibitors. The<a href="https://solaci.org/en/2015/06/24/euromax-early-and-prolonged-infusion-of-bivalirudin-reduces-mortality-in-ami/" title="Read more" >...</a>

The venous thromboembolism is the third most common cardiovascular disease after acute myocardial infarction and stroke . Usual treatment is to use low molecular weight heparin followed by vitamin K antagonists Other studies have shown that the new oral anticoagulants with or without initial heparin are effective alternatives. The endoxaban is a direct Factor Xa<a href="https://solaci.org/en/2015/06/24/hokusai-vte-endoxaban-shows-solid-results-versus-warfarin-in-venous-thromboembolism/" title="Read more" >...</a>

Despite progress in antiplatelet, anticoagulant therapy and invasive strategy, patients with non-ST-segment elevation acute coronary syndrome present an elevated risk of events. There is no consensus on the use of a single anticoagulant which can be administered in the Coronary Unit and also at the time of coronary intervention. The anticoagulant direct factor Xa inhibitor,<a href="https://solaci.org/en/2015/06/24/tao-trial-otamixaban-without-advantages-as-the-only-anticoagulant-in-acute-coronary-syndromes/" title="Read more" >...</a>